BIOGEN INC.

(BIIB)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur BIOGEN INC.
12/05Roche believes cancer drug setback not a fatal blow to growth prospects
10/05Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
10/05Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
06/05Japanese shares rise on energy, financials boost
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
05/05Xbrane Biopharma releases interim report for January – March 2022
05/05Michel Vounatsos to Step Down as Chief Executive Officer of Biogen
04/05MARKETSCREENER'S WORLD PRESS REVIEW : May 4, 2022
03/05BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
03/05Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
03/05Change at the top for Biogen after Alzheimer's drug flops
03/05Biogen's Quarterly Results Fall as Drugmaker Plans to Stop Selling Aduhelm; CEO to Step..
03/05TIMELINE-Biogen CEO to leave as Alzheimer's drug struggles
03/05GLOBAL MARKETS LIVE : BP, Pfizer, Expedia, Citigroup, Amazon...
03/05NACH PROBLEMEN MIT ALZHEIMER-MITTEL : Biogen will Chef austauschen
03/05Nervousness is apparent ahead of Fed speech
03/05SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
03/05Biogen Q1 Non-GAAP EPS, Revenue Drop; CEO Michel Vounatsos to Leave; Reaffirms 2022 Gui..
03/05Biogen gana 535 millones en el trimestre, un 34% menos que en 2021
03/05TRANSCRIPT : Biogen Inc., Q1 2022 Earnings Call, May 03, 2022
03/05BIOGEN INC. : Results of Operations and Financial Condition, Change in Directors or Princi..
03/05Biogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
03/05Biogen Inc. Reaffirms Revenue Guidance for the Full Year 2022
03/05Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
03/05Biogen quarterly profit falls 26%
02/05Biogen, Scribe Therapeutics Expand Research Collaboration to Second Disease Target
02/05Sage, Biogen Start Rolling Submission of New-Drug Application to US FDA for Major Depre..
02/05L'agenda di domani
02/05Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application to U.S..
02/05L'agenda della settimana
30/04BIOGEN : Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in..
29/04L'agenda della prossima settimana
28/04Eli Lilly obesity drug data shines, shares rise
28/04Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
27/04Big Biotech Firms Have Several Catalysts Lined Up, UBS Says
22/04Biogen Withdraws European Marketing Authorization Application for Alzheimer's Disease D..
22/04Biogen pulls application for Alzheimer's drug in Europe
22/04Biogen to withdraw Alzheimer's drug application in Europe
22/04BIOGEN : Update on Regulatory Submission for Aducanumab in the European Union
22/04Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm
20/04BIOGEN : Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics f..
20/04Samsung Biologics Co.,Ltd. completed the acquisition of the remaining 49.9% stake in Sa..
11/04Moody's Downgrades Biogen to Baa2 From Baa1; Outlook Negative
09/04Alzheimer's drugmakers seek accelerated FDA review despite U.S. coverage decision
08/04TIMELINE-Alzheimer's drug from Biogen hits Medicare coverage curbs
08/04MARKETSCREENER'S WORLD PRESS REVIEW : April 8, 2022
08/04SECTOR UPDATE : Health Care Stocks Edge Upward Premarket Friday
08/04SECTOR UPDATE : Health Care
08/04Vir Biotechnology Appoints Johanna Friedl-Naderer as COO
08/04BIOGEN : Statement on the Final National Coverage Determination for Amyloid-Beta Targeting..
07/04U.S. Medicare limits coverage for Biogen's Alzheimer's drug
07/04Medicare Limits Coverage Policy for Biogen's Alzheimer's Drug -- Shares Slide After-Hou..
07/04Medicare Officially Limits Coverage Of Aduhelm To Patients In Clinical Trials- NYT
05/04BIOGEN : to Report First Quarter 2022 Financial Results May 3, 2022
04/04New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerg..
04/04Biogen Inc. Announces New Data from Portfolio of Multiple Sclerosis Therapies
04/04SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioge..
30/03Biogen Submits Final Study Protocol for Alzheimer's Injection to FDA
30/03Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to ..
30/03Biogen Submits Final Protocol for ADUHELM (aducanumab-avwa) Phase 4 Envision Trial to F..
28/03LATE BRIEFING - Unternehmen und Märkte -2-
28/03TRANSCRIPT : Biogen Inc. Presents at Stifel CNS Days, Mar-28-2022 10:15 AM
28/03SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Monday
28/03Wall Street Wavers Pre-Bell as Data-Heavy Week Kicks Off
28/03Top Premarket Decliners
28/03Biogen, Ionis Pharmaceuticals Discontinue Clinical Program for Amyotrophic Lateral Scle..
28/03Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9or..
28/03Biogen Inc. and Ionis Pharmaceuticals, Inc. Announce Topline Phase 1 Study Results of B..
28/03Biogen, Ionis End Development of ALS Candidate After Study Failure
23/03Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE..
23/03InnoCare Pharma Narrows Loss on License-Out Payment From Biogen for Multiple Sclerosis ..
1  2  3  4  5  6  7  8  9  10Suiv.
Prochain événement sur BIOGEN INC.